Health Policy Industry Life Science Medicare 
Health Populi
MARCH 11, 2021
[Note: I may be biased as a University of Michigan graduate of both the School of Public Health and Rackham School of Graduate Studies in Economics]. health care, patient assistance programs, Medicare Advantage plans, and the bundling of proven high-value preventive services into the Affordable Care Act.
Health Populi
MARCH 9, 2022
.” I was particularly keen to dig into this study based on its sponsoring organization: JLL is a real estate services company serving over a dozen vertical markets — including health care, life sciences, senior housing, and retail, among other industry sectors. ” she added. This week, the U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Health Populi
APRIL 16, 2024
Presidential elections to that point, and that the last retiring Baby Boomer enrolls in Medicare that year. Let’s take a walk with “Quincy” through each of the four worlds to see how their health care experience might play out across the key driving forces. In 2030, every Boomer will have been eligible for Medicare.
Health Populi
NOVEMBER 19, 2019
In the past decade, I’ve been spending a lot of time considering SDoH through a variety of lenses across the health/care ecosystem, including care providers like hospitals, health insurance companies, pharma and life science, retail health care front doors, and non-profits and foundations.
Health Populi
JUNE 24, 2021
I welcomed the opportunity to learn from this team’s approach in weaving together the dynamic issues that help us to plan for the long-tail of COVID-19 and its impact on the economy and prospects for the health care industry and health citizens. spends on NASA.
Health Populi
OCTOBER 28, 2019
Hospital costs contribute to rising medical costs to 49% of health consumers. patients’ negative views of the pharmaceutical industry in this study was the opioid epidemic. A recent study on politics and health care spending in the U.S. Physician fees are cited as cost-contributing by only 18% of patients.
Henry Kotula
JULY 1, 2019
The trend has implications for employers, payers, providers and even pharmaceutical and life science companies. For payers, it becomes important to benchmark the prices paid commercially against a common reference point such as Medicare. WHAT ELSE YOU SHOULD KNOW.
Expert insights. Personalized for you.
245 
Let's personalize your content